RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$25.98

28 Oct
2020

0.880

OPEN

$25.76

3.51%

HIGH

$26.22

0

LOW

$25.76

TARGET
$25.205 -3.0% downside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . RAP . RVA . MEB . AHX . PCK . CMP . CYC . IMR . VTI . AT1 .
MARKET CONSENSUS FORECAST
RMD: 1
Title FY21
Forecast
FY22
Forecast
EPS (cps) 70.2 xxx
DPS (cps) 23.9 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 36.3 xxx
Dividend Yield 0.9% xxx
Div Pay Ratio(%) 34.1% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.46%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.61

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 19/08 - 3.8c (0%)

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.1

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

5

xxxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

26/10/2020

3

Equal-weight

$25.90

-0.31%

ResMed will publish its first quarter earnings on October 29 (US time). Morgan Stanley suspects the uplift from ventilators sales will have peaked in the fourth quarter and the positive revisions to earnings have played out for the short term.

The business is expected to emerge from the pandemic in good condition although the valuation keeps the broker's rating at Equal-weight. Target is raised to $25.90 from $25.40. Industry view: In-Line.

FORECAST
Morgan Stanley forecasts a full year FY21 dividend of 22.88 cents and EPS of 72.17 cents.
Morgan Stanley forecasts a full year FY22 dividend of 22.88 cents and EPS of 81.12 cents.

Ord Minnett

xx/xx/xxxx

4

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

RMD STOCK CHART